LC3B-II in autophagy drug discovery: the biomarker that still matters.

Why LC3B-II remains an established marker in autophagy research

Autophagy is a tightly regulated cellular process that maintains homeostasis by degrading and recycling damaged organelles, protein aggregates, and other intracellular components. As its role in disease has become increasingly clear, autophagy has emerged as an important area of research in oncology, neuroscience, immunology, and metabolic disorders.^5,6

While the field has expanded to include topics such as selective autophagy, lysosomal biology, and autophagic flux, one biomarker has remained consistently prominent: LC3B-II[NW1.1]. This lipidated form of the LC3B protein associates with the membrane of newly formed autophagosomes, making it a standard readout for monitoring autophagosome formation.^7,8

Measuring LC3B-II is valuable for determining whether compounds influence the autophagy pathway. In early-stage drug discovery, LC3B-II is frequently used to characterize pathway activity, evaluate target engagement, and compare the effects of candidate molecules across experimental conditions.^3,4

The challenge of interpreting LC3B-II data

However, interpreting LC3B-II data requires careful consideration. An increase in LC3B-II may indicate enhanced autophagy initiation, but it can also result from impaired autophagosome degradation if fusion with lysosomes is blocked. For this reason, researchers increasingly evaluate LC3B-II alongside complementary assays that provide a more complete picture of autophagic flux.^2,9

Common approaches include monitoring p62/SQSTM1 degradation, using lysosomal inhibitors to assess flux, and employing fluorescent LC3 reporters to visualize autophagosome formation and maturation. Depending on the biological question, investigators may also incorporate markers of lysosomal function or selective autophagy pathways, such as mitophagy or lysophagy.^2,9

Together, these complementary assays provide a clearer understanding of how therapeutic candidates affect the autophagy pathway. LC3B-II remains a well-established starting point, but it is most powerful when interpreted within the broader context of autophagic flux and cellular function.^2,9

A better approach to autophagy research

Although autophagy research continues to evolve, LC3B-II remains one of the most widely used biomarkers for studying this complex pathway. Choosing the appropriate detection method and understanding how to interpret the results alongside complementary assays is essential for generating meaningful data in drug discovery research.^1,2

Revvity's HTRF™ LC3B-II assay was developed to help researchers overcome the challenges they faced when quantifying this critical autophagy marker. Its no-wash, homogeneous format reduces the variability and workflow complexity associated with traditional Western blot approaches. By providing a more reliable, quantitative readout of LC3B-II levels, the HTRF assay empowers you to make better-informed decisions about how your compounds are affecting the autophagy pathway.

To complement the LC3B-II assay, Revvity also offers no-wash detection kits for measuring p62/SQSTM1, a complementary marker that can be used to assess autophagic flux. Together, these solutions allow quantitative monitoring of how samples are responding across key autophagy markers.

To learn more about Revvity's HTRF autophagy assays and how they can enhance your research, watch our on-demand webinar. Our experts dive deep into the science behind these innovative approaches, share real-world data, and discuss practical strategies for generating high-quality, biologically relevant results.